Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial.

Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial.

OBJECTIVE: Circulating levels of soluble receptor for advanced glycation end products (sRAGE) likely comprise both a secreted isoform (esRAGE) and wild-type RAGE cleaved from the cell membrane. Both sRAGE and esRAGE have been proposed as biomarkers of cardiovascular disease (CVD), but prospective d...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Colhoun, H, Betteridge, D, Durrington, P, Hitman, G, Neil, A, Livingstone, S, Charlton-Menys, V, Bao, W, Demicco, D, Preston, G, Deshmukh, H, Tan, K, Fuller, J
Formáid:	Journal article
Teanga:	English
Foilsithe / Cruthaithe:	2011

Míreanna comhchosúla

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
de réir: Colhoun, H, et al.
Foilsithe / Cruthaithe: (2009)

C-reactive Protein and Amyloid A as Predictors of Cardiovascular Events in Type 2 Diabetes in CARDS
de réir: Charlton-Menys, V, et al.
Foilsithe / Cruthaithe: (2009)

Erratum: Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: The Collaborative Atorvastatin Diabetes Study (CARDS)
de réir: Charlton-Menys, V, et al.
Foilsithe / Cruthaithe: (2009)

Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).
de réir: Charlton-Menys, V, et al.
Foilsithe / Cruthaithe: (2009)

Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS).
de réir: Charlton-Menys, V, et al.
Foilsithe / Cruthaithe: (2009)

Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
de réir: Neil, H, et al.
Foilsithe / Cruthaithe: (2006)

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
de réir: Colhoun, H, et al.
Foilsithe / Cruthaithe: (2004)

Effect of atorvastatin in patients 65 years of age with type 2 diabetes: Subgroup analysis from the collaborative atorvastatin diabetes study (CARDS)
de réir: DeMicco, D, et al.
Foilsithe / Cruthaithe: (2005)

Change in Lp-PLA2 With Risk Change on Statin Therapy in the Collaborative Atorvastatin Diabetes Study (CARDS)
de réir: Betteridge, D, et al.
Foilsithe / Cruthaithe: (2009)

Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS).
de réir: Raikou, M, et al.
Foilsithe / Cruthaithe: (2007)

Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).
de réir: Colhoun, H, et al.
Foilsithe / Cruthaithe: (2005)

Safety of atorvastatin in the collaborative AtoRvastatin diabetes study (CARDS)
de réir: Newman, C, et al.
Foilsithe / Cruthaithe: (2006)

The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS).
de réir: Newman, C, et al.
Foilsithe / Cruthaithe: (2008)

Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS).
de réir: Hitman, G, et al.
Foilsithe / Cruthaithe: (2007)

Effect of atorvastatin on stroke in the collaborative atorvastatin diabetes study (CARDS): Factors predictive of the risk of stroke
de réir: Newman, C, et al.
Foilsithe / Cruthaithe: (2005)

Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes.
de réir: Thomason, M, et al.
Foilsithe / Cruthaithe: (2004)

The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease
de réir: Soedamah-Muthu, S, et al.
Foilsithe / Cruthaithe: (2011)

Cost-effectiveness of atorvastatin (10mg) in patients with type 2 diabetes without coronary heart disease: CARDS trial analysis and extrapolation
de réir: Raikou, M, et al.
Foilsithe / Cruthaithe: (2005)

Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes.
de réir: Colhoun, H, et al.
Foilsithe / Cruthaithe: (2002)

Effect of atorvastatin on stroke in patients with type 2 diabetes: factors predicting the risk of stroke in the Collaborative Atorvastatin Diabetes Study (CARDS)
de réir: Hitman, G, et al.
Foilsithe / Cruthaithe: (2005)

The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.
de réir: Soedamah-Muthu, S, et al.
Foilsithe / Cruthaithe: (2003)

Bone-Targeting Endogenous Secretory Receptor for Advanced Glycation End Products Rescues Rheumatoid Arthritis
de réir: Tatsuo Takahashi, et al.
Foilsithe / Cruthaithe: (2013-06-01)

Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)
de réir: Harshal A. Deshmukh, et al.
Foilsithe / Cruthaithe: (2012-05-01)

Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes
de réir: Morcos Michael, et al.
Foilsithe / Cruthaithe: (2007-03-01)

Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes
de réir: Deedwania, PC, et al.
Foilsithe / Cruthaithe: (2016)

1 h Postload Glycemia Is Associated with Low Endogenous Secretory Receptor for Advanced Glycation End Product Levels and Early Markers of Cardiovascular Disease
de réir: Antonino Di Pino, et al.
Foilsithe / Cruthaithe: (2019-08-01)

Concentration of Endogenous Secretory Receptor for Advanced Glycation End Products and Matrix Gla Protein in Controlled and Uncontrolled Type 2 Diabetes Mellitus Patients
de réir: Dwi Yuniati Daulay, et al.
Foilsithe / Cruthaithe: (2013-04-01)

Serum Level of Soluble Receptor for Advanced Glycation End Products Is Associated with A Disintegrin And Metalloproteinase 10 in Type 1 Diabetes.
de réir: Alan C H Lee, et al.
Foilsithe / Cruthaithe: (2015-01-01)

Status report of lipid-lowering trials in diabetes.
de réir: Betteridge, D, et al.
Foilsithe / Cruthaithe: (2000)

Effects of methanolic extracts from edible plants on endogenous secretory receptor for advanced glycation end products induced by the high glucose incubation in human endothelial cells
de réir: Yoshinori Okada, et al.
Foilsithe / Cruthaithe: (2015-01-01)

Increased C-reactive protein levels in overweight and obese women taking exogenous hormones: the United Kingdom Women's Heart Study (UKWHS).
de réir: Kwok, S, et al.
Foilsithe / Cruthaithe: (2009)

Enhancement of pea protein solubility and thermal stability for acidic beverage applications via endogenous Maillard-induced glycation and chromatography purification
de réir: Alissa A. Schneider, et al.
Foilsithe / Cruthaithe: (2023-01-01)

Inverse association between glycated albumin and insulin secretory function may explain higher levels of glycated albumin in subjects with longer duration of diabetes.
de réir: Yong-ho Lee, et al.
Foilsithe / Cruthaithe: (2014-01-01)

Comparison of the risk of fatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: a prospective registry study.
de réir: Neil, H, et al.
Foilsithe / Cruthaithe: (2003)

Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study.
de réir: Neil, H, et al.
Foilsithe / Cruthaithe: (2005)

Endogenous advanced glycation end products in the pathogenesis of chronic diabetic complications
de réir: Misganaw Asmamaw Mengstie, et al.
Foilsithe / Cruthaithe: (2022-09-01)

Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD
de réir: Katherine A. Pratte, et al.
Foilsithe / Cruthaithe: (2021-04-01)

Endogenous Secretory RAGE as a Novel Biomarker for Metabolic Syndrome and Cardiovascular Diseases
de réir: Hidenori Koyama, et al.
Foilsithe / Cruthaithe: (2007-01-01)

Endogenous and Exogenous Regulatory Signaling in the Secretory Pathway: Role of Golgi Signaling Molecules in Cancer
de réir: Simona Del Giudice, et al.
Foilsithe / Cruthaithe: (2022-03-01)

Soluble Receptor for Glycation End-products Concentration Increases Following the Treatment of Severe Diabetic Ketoacidosis
de réir: William H. Hoffman, et al.
Foilsithe / Cruthaithe: (2020-06-01)